Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Apr;99(14):e19638.
doi: 10.1097/MD.0000000000019638.

Prognostic significance of lymphocyte monocyte ratio in patients with ovarian cancer

Linrui Cai  1 , Yanlin Song  2 , Xia Zhao  1
Affiliations
Meta-Analysis

Prognostic significance of lymphocyte monocyte ratio in patients with ovarian cancer

Linrui Cai et al. Medicine (Baltimore). 2020 Apr.

Abstract

Background: This study aimed to systematically assess the prognostic value of lymphocyte monocyte ratio (LMR) in patients with ovarian cancer through performing a meta-analysis.

Methods: Web of Science, PubMed, EMBASE, Cochrane Library, and China National Knowledge Infrastructure databases were searched for potentially eligible studies. The baseline characteristics and relevant data were extracted. Hazard ratios with 95% confidence intervals (CIs) were combined to assess the prognostic value of LMR in patients with ovarian cancer.

Results: Nine studies enrolling 2809 patients were included. The pooled hazard ratios of lower LMR for overall survival and progression free survival in patients with ovarian cancer were 1.71 (95% CI, 1.40-2.09) and 1.68 (95% CI, 1.49-1.88), respectively. Subgroup analysis and sensitivity analysis were also performed. No significant publication bias was found.

Conclusion: Our results suggested that lower LMR was associated with poorer overall survival and progression free survival in patients with ovarian cancer. The findings may assist prognosis evaluation and future research on therapies based on modulating host immune response in ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Selection process of studies.
Figure 2
Figure 2
Pooled HR of lower LMR for OS (A) and PFS (B) in patients with ovarian cancer. HR = hazard ratio, LMR = lymphocyte monocyte ratio, OS = overall survival, PFS = progression free survival.
Figure 3
Figure 3
The Begg plots of publication bias of the studies for OS (A) and PFS (B). S = overall survival, PFS = progression free survival.
See this image and copyright information in PMC

References

    1. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61:183–203. - PMC - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Polterauer S, Vergote I, Concin N, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer 2012;22:380–5. - PubMed
    1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519–29. - PubMed
    1. Zhu JY, Liu CC, Wang L, et al. Peripheral blood lymphocyte-to-monocyte ratio as a prognostic factor in advanced epithelial ovarian cancer: a multicenter retrospective study. J Cancer 2017;8:737–43. - PMC - PubMed